Arcus Biosciences Inc (NYSE: RCUS) on Tuesday, soared 6.76% from the previous trading day, before settling in for the closing price of $21.3. Within the past 52 weeks, RCUS’s price has moved between $6.50 and $26.40.
During the last 5-year period, the sales drop of Healthcare Sector giant was -10.20%. The company achieved an average annual earnings per share of -14.23%. With a float of $81.39 million, this company’s outstanding shares have now reached $107.10 million.
Arcus Biosciences Inc (RCUS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 34.22%, while institutional ownership is 52.84%. The most recent insider transaction that took place on Jan 05 ’26, was worth 681,342. In this transaction President of this company sold 31,823 shares at a rate of $21.41, taking the stock ownership to the 922,240 shares. Before that another transaction happened on Jan 05 ’26, when Company’s Officer proposed sale 31,823 for $21.77, making the entire transaction worth $692,787.
Arcus Biosciences Inc (RCUS) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -1.03 earnings per share (EPS) for the period topping the consensus outlook (set at -1.2) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.68% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 3.65 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.43, a number that is poised to hit -1.10 in the next quarter and is forecasted to reach -3.86 in one year’s time.
